TSP-9 test for Barrett's esophagus :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

TSP-9 test revolutionizes Barrett's esophagus management with positive results

Barrett’s esophagus Barrett’s esophagus
Barrett’s esophagus Barrett’s esophagus

What's new?

Using tissue systems pathology-9 (TSP-9) test enables physicians to improve their capacity to accurately assess the risk of disease progression in Barrett's esophagus.

A three-arm randomized controlled trial depicted that the tissue systems pathology-9 (TSP-9) test had the potential to enhance health outcomes by facilitating risk-aligned decision-making for treating Barrett's esophagus. Researchers aimed to assess whether the TSP-9 test had a positive impact on adherence to clinical guidelines for the management of Barrett's esophagus.

This trial was executed utilizing two different approaches. In intervention 1, participants were given TSP-9 results, while in intervention 2, volunteers were given the choice to request TSP-9 results. Data was gathered from 259 practising gastrointestinal surgeons and gastroenterologists who assessed and determined the management for three simulated Barrett's esophagus subject categories: those with non-dysplastic Barrett's esophagus, those with an indefinite dysplasia status, and those with low-grade dysplasia.

Intervention 1 exhibited a notable increase in the accurate assessment of the risk of progression to high-grade dysplasia/esophageal adenocarcinoma and the provision of treatment as per U.S. society guidelines when compared to the control group (+6.9% to +12.3%). No discernable difference was witnessed in the utilization of guideline-recommended endoscopic eradication therapy. However, in cases necessitating annual endoscopic surveillance, a substantial enhancement was observed in adherence within intervention 1, showing a difference-in-difference of +18.5%.

In intervention 2, the TSP-9 test was requested in 21.9% of cases. Those who ordered the test demonstrated performance similar to that of intervention 1, while those who did not were comparable to the control group. The TSP-9 test enhanced compliance with clinical guidelines for monitoring and treating people with Barrett's esophagus, whether they were at high or low risk of disease progression.

Source:

Clinical and Translational Gastroenterology

Article:

A Randomized Controlled Study on Clinical Adherence to Evidence-Based Guidelines in the Management of Simulated Patients with Barrett's Esophagus and the Clinical Utility of a Tissue Systems Pathology Test: Results from Q-TAB

Authors:

John W Peabody et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: